30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Integra LifeSciences Reports 1Q18 Orthopaedic Revenue -

ORTHOWORLD estimates Integra LifeSciences’ (IART) 1Q18 orthopaedic revenue at US $24.8M, -4.8% from 1Q17.

Estimated segment sales and growth follow.

  1Q18 1Q17 $ Change % Change
 Joint Recon Extremities $9.7  $9.4  $0.3  3.2% 
 Trauma $15.1  $16.7  -$1.5  -9.2% 
Total   $24.8  $26.1  -$1.2  -4.8% 

Please note, we have revised all IART 2017 quarterly estimates upward based on new information; this increased our overall 2017 orthopaedic revenue estimate by ~$10MM to reach $117.4MM. We constantly seek to refine all revenue estimates and most definitely welcome ORTHOWORLD Members’ input.

Ankle and shoulder replacements remain high performers for Integra with both achieving double-digit growth in the quarter, a consistent trend since last year. Leadership noted that IART’s ankle business is at about $20MM, and shoulder is in the $15MM range. (Other joint recon revenue includes hand, wrist and elbow.) Lower extremities trauma is reported to be down in double-digits, and leadership acknowledged the need to bring in updated plating and locking systems, which are in the works. Further, sales teams experienced reduced selling time due to territory realignment and training.

New products offered by dedicated extremity orthopaedic sales channels will accelerate organic growth in 2H18. Specifically, the Panta II fusion nail for ankle fixation is expected to launch. Further, in late 4Q, trialing will commence for a new total ankle revision system in the U.S.—which, notably, will support revision of competitive ankles, as well.

Source: Integra LifeSciences, ORTHOWORLD estimates




This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.